-
公开(公告)号：US20120157449A1
公开(公告)日：2012-06-21
申请号：US13313045
申请日：2011-12-07
Applicant: Rosa Maria Rodriguez Sarmiento , Juergen Wichmann
Inventor： Rosa Maria Rodriguez Sarmiento , Juergen Wichmann
IPC: A61K31/541 , A61K31/4525 , A61K31/453 , C07D413/14 , A61K31/5377 , C07D405/14 , A61K31/4709 , A61K31/4545 , A61K31/496 , C07D409/14 , A61K31/4535 , C07D417/14 , A61K31/454 , A61P25/18 , A61P25/24 , A61P25/22 , A61P25/30 , A61P25/00 , A61P25/28 , C07D405/10
CPC classification number: C07D405/10
Abstract: The present invention is concerned with novel dual modulators of the 5-HT2A and D3 receptors of formula (I) wherein n, x, Y, R1, R2, R3, and R4 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as pharmaceuticals.
Abstract translation: 本发明涉及式（I）的5-HT2A和D3受体的新型双重调节剂，其中n，x，Y，R 1，R 2，R 3和R 4如本文所述，以及其药学上可接受的盐和酯 其中。 此外，本发明涉及制备式（I）化合物，包含它们的药物组合物及其作为药物的用途。
-
公开(公告)号：US20120010201A1
公开(公告)日：2012-01-12
申请号：US13171499
申请日：2011-06-29
Applicant: Luca Gobbi , Rosa Maria Rodriguez Sarmiento , Juergen Wichmann
Inventor： Luca Gobbi , Rosa Maria Rodriguez Sarmiento , Juergen Wichmann
IPC: A61K31/541 , A61K31/496 , A61P25/18 , A61K31/5377 , C07D417/14 , C07D493/04 , C07D413/14
CPC classification number: C07D495/04 , C07D491/048
Abstract: The present invention is concerned with novel dual modulators of the 5-HT2A and D3 receptors of formula (I) wherein X, Y, A, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as therapeutics.
Abstract translation: 本发明涉及式（I）的5-HT2A和D3受体的新型双重调节剂，其中X，Y，A，R 1，R 2和R 3如本文所述，以及其药学上可接受的盐和酯。 此外，本发明涉及制备式（I）化合物，包含它们的药物组合物及其作为治疗剂的用途。
-
公开(公告)号：US20110313151A1
公开(公告)日：2011-12-22
申请号：US13161548
申请日：2011-06-16
Applicant: Luca Gobbi , Rosa Maria Rodriguez Sarmiento , Juergen Wichmann
Inventor： Luca Gobbi , Rosa Maria Rodriguez Sarmiento , Juergen Wichmann
IPC: C07D491/048 , C07D495/04
CPC classification number: C07D491/048 , C07D495/04
Abstract: The present invention is concerned with novel dual modulators of the 5-HT2A and D3 receptors of formula (I) wherein X, Y, A, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as therapeutics.
Abstract translation: 本发明涉及式（I）的5-HT2A和D3受体的新型双重调节剂，其中X，Y，A，R 1，R 2和R 3如本文所述，以及其药学上可接受的盐和酯。 此外，本发明涉及制备式（I）化合物，包含它们的药物组合物及其作为治疗剂的用途。
-
公开(公告)号：US20100152193A1
公开(公告)日：2010-06-17
申请号：US12626982
申请日：2009-11-30
Applicant: Daniela Alberati , Luca Gobbi , Matthias Koerner , Bernd Kuhn , Jens-Uwe Peters , Rosa Maria Rodriguez-Sarmiento , Mark Rogers-Evans , Markus Rudolph
Inventor： Daniela Alberati , Luca Gobbi , Matthias Koerner , Bernd Kuhn , Jens-Uwe Peters , Rosa Maria Rodriguez-Sarmiento , Mark Rogers-Evans , Markus Rudolph
IPC: A61K31/501 , C07D403/04 , A61P25/18
CPC classification number: C07D403/04 , C07D403/14 , C07D405/14
Abstract: The present invention is concerned with novel pyridazinones of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used for the treatment of CNS disorders.
Abstract translation: 本发明涉及式（I）的新的哒嗪酮，其中R1，R2，R3和R4如说明书和权利要求书中所定义，以及其生理上可接受的盐和酯。 这些化合物抑制PDE10A，可用于治疗CNS疾病。
-
公开(公告)号：US07608617B2
公开(公告)日：2009-10-27
申请号：US11821263
申请日：2007-06-22
Applicant: Silvia Gatti McArthur , Cornelia Hertel , Matthias Heinrich Nettekoven , Jean-Marc Plancher , Susanne Raab , Olivier Roche , Rosa Maria Rodriguez-Sarmiento , Franz Schuler
Inventor： Silvia Gatti McArthur , Cornelia Hertel , Matthias Heinrich Nettekoven , Jean-Marc Plancher , Susanne Raab , Olivier Roche , Rosa Maria Rodriguez-Sarmiento , Franz Schuler
IPC: A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/5377 , A61K31/541 , C07D401/10 , C07D217/06 , C07D417/10 , C07D211/06 , C07D413/10
CPC classification number: C07D401/10 , C07D205/04 , C07D207/06 , C07D207/12 , C07D207/14 , C07D209/44 , C07D211/22 , C07D211/38 , C07D211/42 , C07D211/46 , C07D217/06 , C07D295/088 , C07D295/192
Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositions containing them. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐，用于制备这些化合物和含有它们的药物组合物。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
Patent Agency Ranking
公开(公告)号：US07528135B2
公开(公告)日：2009-05-05
申请号：US11290675
申请日：2005-11-30
IPC: A61K31/496 , C07D213/40 , C07D213/82
CPC classification number: C07D213/74 , C07D213/82 , C07D213/83
Abstract: The present invention relates to compounds of formula I wherein R1, R2 and A are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical composition comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
Abstract translation: 本发明涉及式I化合物，其中R 1，R 2和A如说明书和权利要求书中所定义，及其药学上可接受的盐以及包含这些化合物的药物组合物及其制备方法。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
公开(公告)号：US07456210B2
公开(公告)日：2008-11-25
申请号：US11190626
申请日：2005-07-27
Applicant: Rosa Maria Rodriguez-Sarmiento , Wolfgang Wostl , Rene Wyler
Inventor： Rosa Maria Rodriguez-Sarmiento , Wolfgang Wostl , Rene Wyler
IPC: A61K31/4015 , C07D207/12
CPC classification number: C07D207/26 , C07D207/277 , C07D403/04 , C07D413/04 , C07D417/04
Abstract: The present invention relates to compounds of formula I wherein R1 and R2 are as defined in the specification and to pharmaceutically acceptable salts thereof for the treatment of diseases, which are mediated by monoamine oxidase B inhibitors, for example Alzheimer's disease and senile dementia.
Abstract translation: 本发明涉及式I化合物，其中R 1和R 2定义如本说明书及其药学上可接受的盐，用于治疗疾病，其是介导的 通过单胺氧化酶B抑制剂，例如阿尔茨海默病和老年痴呆。
-
公开(公告)号：US07361682B2
公开(公告)日：2008-04-22
申请号：US11157093
申请日：2005-06-20
Applicant: Silvia Gatti McArthur , Cornelia Hertel , Matthias Heinrich Nettekoven , Susanne Raab , Olivier Roche , Rosa Maria Rodriguez-Sarmiento , Franz Schuler , Jean-Marc Plancher
Inventor： Silvia Gatti McArthur , Cornelia Hertel , Matthias Heinrich Nettekoven , Susanne Raab , Olivier Roche , Rosa Maria Rodriguez-Sarmiento , Franz Schuler , Jean-Marc Plancher
IPC: A61K31/55 , A61K31/541 , A61K31/5377 , A61K31/454 , A61K31/4545 , A61K31/4045 , C07D209/42 , C07D401/02 , C07D413/02 , C07D417/02
CPC classification number: C07D405/14 , C07D209/42 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14
Abstract: The present invention relates to compounds of formula I: wherein X, R1, R2, R3, R4 and R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositions containing them. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
Abstract translation: 本发明涉及式I化合物：其中X，R 1，R 2，R 3，R 4， SUP和R 5如在说明书和权利要求书及其药学上可接受的盐中所定义，用于制备这些化合物和含有它们的药物组合物。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
公开(公告)号：US07253318B2
公开(公告)日：2007-08-07
申请号：US11156417
申请日：2005-06-20
Applicant: Synese Jolidon , Rosa Maria Rodriguez-Sarmiento , Andrew William Thomas , Wolfgang Wostl , Rene Wyler
Inventor： Synese Jolidon , Rosa Maria Rodriguez-Sarmiento , Andrew William Thomas , Wolfgang Wostl , Rene Wyler
IPC: C07C233/65 , A61K31/165
CPC classification number: C07C255/54 , C07C235/20
Abstract: The invention relates to compounds of the formula and their pharmaceutically acceptable salts wherein R1, R2, R3, R4, R5, n, m, and o are as defined in the specification. The compounds are selective monoamine oxidase β inhibitors and are useful for the treatment and prevention of Alzheimer's disease and senile dementia, as well as other CNS disorders. The invention also relates to processes for preparing such compounds and pharmaceutical compositions containing them.
Abstract translation: 本发明涉及下式的化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4， / SUP>，R 5，n，m和o如说明书中所定义。 这些化合物是选择性单胺氧化酶β抑制剂，并且可用于治疗和预防阿尔茨海默氏病和老年痴呆以及其它CNS疾病。 本发明还涉及制备这些化合物的方法和含有它们的药物组合物。
-
公开(公告)号：US06846832B2
公开(公告)日：2005-01-25
申请号：US10625116
申请日：2003-07-22
Applicant: Synese Jolidon , Rosa Maria Rodriguez-Sarmiento , Andrew William Thomas , Rene Wyler
Inventor： Synese Jolidon , Rosa Maria Rodriguez-Sarmiento , Andrew William Thomas , Rene Wyler
IPC: A61K31/4035 , A61K31/405 , A61P1/14 , A61P3/00 , A61P3/04 , A61P25/00 , A61P25/02 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/32 , A61P25/34 , A61P43/00 , C07D209/46 , C07D209/48 , C07D471/04 , A61K31/435 , C07D209/44 , C07D221/02
CPC classification number: C07D471/04 , C07D209/46
Abstract: 2,3-Dihydro-isoindol-1-one derivatives, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them, for the prevention and treatment of diseases which are mediated by monoamine oxidase B.
Abstract translation: 2,3-二氢 - 异吲哚-1-酮衍生物，其制备方法，它们作为药物的用途和包含它们的药物组合物，用于预防和治疗由单胺氧化酶B介导的疾病。
-
-
-
-
-
-
-
-
-
Search Results
65
records
(took 0.034 seconds)
